ArticleOncology letters2026
Stage IIIB pulmonary sarcomatoid carcinoma treated with spatially fractionated radiotherapy combined with antiangiogenic therapy and sequential chemo-immunotherapy: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer, characterized by high invasiveness and treatment resistance. Patients with PSC often exhibit poor treatment outcomes, short median survival and a dismal prognosis, necessitating novel comprehensive treatment strategies to address this clinical challenge. A 64-year-old man with PSC was initially diagnosed with stage cT4N2M0 IIIB disease and was negative for programmed cell death-ligand 1 expression. Owing to the large tumor size and unfavorable performance status, treatment initially involved an induction regimen that combined tomotherapy-based spatially fractionated radiotherapy (SFRT) with recombinant human endostatin injection (Endostar). As the condition of the patient improved, two additional cycles of low-dose albumin-bound paclitaxel were administered as concurrent chemoradiotherapy. Following radiotherapy, the patient received two sequential cycles of systemic therapy with paclitaxel liposome and ivonescimab. This combined regimen demonstrated favorable short-term efficacy with improved performance status. However, the patient developed pneumonia caused by infection with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.